For the quarter ending 2026-03-31, ACRS had $8,700K increase in cash & cash equivalents over the period. -$18,162K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -19,824 | -19,795 | -14,614 | -30,514 |
| Depreciation and amortization | 102 | 102 | 110 | 242 |
| Stock-based compensation expense | 3,198 | 2,926 | 2,860 | 6,598 |
| Revaluation of contingent consideration | - | 400 | 100 | 1,800 |
| Accounts receivable | - | - | - | -124 |
| Accounts receivable, prepaid expenses and other assets | -742 | 672 | -6,810 | - |
| Accounts payable | 1,513 | 3,963 | 377 | 4,107 |
| Prepaid expenses and other assets | - | - | - | -7,031 |
| Accrued expenses and other liabilities | -3,026 | 1,251 | 1,295 | -10,643 |
| Deferred income | -854 | -1,306 | -715 | -1,795 |
| Net cash used in operating activities | -18,149 | -13,131 | -10,932 | -23,050 |
| Purchases of property and equipment | 13 | 24 | 23 | 64 |
| Purchases of marketable securities | 51,669 | 4,608 | 5,198 | 29,926 |
| Proceeds from sales and maturities of marketable securities | 20,750 | 15,001 | 19,051 | 54,989 |
| Payment of deferred transaction consideration for in-licensed assets | - | - | 0 | 833 |
| Payments of deferred transaction consideration for in-licensed assets | - | 833 | - | - |
| Net cash (used in) provided by investing activities | -30,932 | 10,369 | 13,830 | 24,166 |
| Payments of deferred transaction consideration for in-licensed assets | - | 2,372 | 3,044 | - |
| Proceeds from issuance of common stock under the at-the-market sales agreement, net of issuance costs | 57,880 | - | - | - |
| Payments of employee withholding taxes related to restricted stock unit award vesting | 250 | 162 | 0 | 284 |
| Proceeds from exercise of employee stock options and the issuance of stock | 151 | - | - | - |
| Net cash provided by (used in) financing activities | 57,781 | -2,534 | -3,044 | -284 |
| Net increase in cash and cash equivalents | 8,700 | -5,296 | -146 | 832 |
| Cash and cash equivalents at beginning of period | 19,960 | 25,256 | 24,570 | - |
| Cash and cash equivalents at end of period | 28,660 | 19,960 | 25,256 | - |
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)